Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

While GLP-1 therapies like Ozempic gain traction, personalized peptide therapies are supporting long-term health goals ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

insulin, and safety results. The success of these studies is a true testament to the effectiveness, versatility, and promise of our proprietary DehydraTECH TM technology platform within, and outside ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look ...

The term "blue chip" originated from poker, where blue chips were the highest denomination of chips used in the game.

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant in recent months.